Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-01-29

Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 study evaluating the efficacy and safety of ABC008 for inclusion body myositis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABC008

Snippet

Sponsor: Abcuro, Inc. | Conditions: Inclusion Body Myositis | Phase 2, Phase 3 | Status: COMPLETED